The statements below are Merchant Law Group’s account of this case. They reflect allegations or the firm’s position and have not been determined by a court unless a settlement or judgment is noted.
About This Case
Eliquis (apixaban) is an anti-coagulant (blood thinner) jointly developed and commercialized by Bristol-Myers Squibb and Pfizer, and approved for use in Canada. Eliquis is prescribed to treat or prevent conditions such as deep vein thrombosis, pulmonary embolism, as well as atrial fibrillation and sometimes following certain surgeries to prevent strokes that can occur as a result of blood clots. Use of Eliquis allegedly causes uncontrollable bleeding and hemorrhaging that can cause serious injuries and death.
Source: Merchant Law Group
How to Register
IF YOU WISH TO JOIN THE CONTACT LIST REGARDING THIS CLASS ACTION, PLEASE COMPLETE THE BELOW FORM. (Please note, providing your contact information creates no lawyer-client relationship or financial obligation. You are not charged any fee or cost for joining the contact list for this class action – our law firm would likely paid a contingency fee from the compensation recovered, if this class action is successful.)
Source: Merchant Law Group
Disclaimer: This information is sourced from Merchant Law Group. It is provided for general information only and does not constitute legal advice. Always verify details with the original source before taking any action.
Legal disclaimer: Information on this page is general in nature and does not constitute legal advice. ClaimBar tracks class action settlements and provides updates. Always seek professional legal advice for your specific circumstances.
Did this page answer your question?